Skip to main content
Log in

Who killed Jesse Gelsinger? Ethical issues in human gene therapy

  • Published:
Monash Bioethics Review Aims and scope Submit manuscript

Abstract

Gene therapy, while promising, is a relatively new field fraught with many benefits but even bigger pitfalls. Last year, Jesse Gelsinger became the first casualty in the race to discover a gene therapy cure. The death of Gelsinger was the result of several factors that came together at an inopportune time. His death highlighted the inadequacies in the regulation of gene therapy and shed light on several questionable decisions made by the doctors overseeing his case. There is no doubt that the Gelsinger case will affect how we pursue genetic therapy but the question is how?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shrebnivas, S. Who killed Jesse Gelsinger? Ethical issues in human gene therapy. Monash Bioethics Review 19, 35–43 (2000). https://doi.org/10.1007/BF03351239

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03351239

Keywords

Navigation